Cancer drug combo trial for rare blood diseases withdrawn before starting
NCT ID NCT06284460
First seen Feb 14, 2026 · Last updated May 16, 2026 · Updated 17 times
Summary
This study was designed to test a new combination of two drugs (ASTX727 and ASTX029) for people with certain types of blood cancers (MDS or MDS/MPN) that have a RAS gene mutation. The goal was to find a safe dose and see if it could control the disease. However, the study was withdrawn before any participants were enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOPROLIFERATIVE NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Cente
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.